ライフサイエンスコーパス: arrhythmic

1 ould be classified as cardiovascular but not arrhythmic.

2 this oscillator and that the elf4 mutant is arrhythmic.

3 Both arrhythmic (1/f-type) and rhythmic (band) activities wer

4 Our results show that the main source of arrhythmic activity was localized to the higher-order th

5 This arrhythmic activity was localized to the higher-order th

6 f action potential duration with evidence of arrhythmic activity, parameters which could not have bee

7 nalogue of a benzoxathiin that has high anti-arrhythmic activity.

8 ted epicardial action potential notch but no arrhythmic activity.

9 It is the first 'anti-arrhythmic' adaptive response in the setting of AF and a

10 o MSG-treated hamsters that became circadian arrhythmic after DPS, both dark-phase and light-phase UR

11 The actions of multi-channel class III anti-arrhythmic agents vernakalant and amiodarone were introd

12 r AP morphology are the primary cause of pro-arrhythmic alternans.

13 t hemodialysis enrolled in the Predictors of Arrhythmic and Cardiovascular Risk in End Stage Renal Di

14 endpoint of cardiovascular death, and major arrhythmic and major heart failure events.

15 r1/2-null SCN, mCry1-luc bioluminescence was arrhythmic and no longer suppressed by elevation of cAMP

16 idence of phenotypic progression and adverse arrhythmic and nonarrhythmic events over long-term follo

17 d natural history studies of LMNA-associated arrhythmic and nonarrhythmic outcomes are limited, and t

18 This study sought to describe the arrhythmic and nonarrhythmic outcomes of LMNA mutation c

19 These arrhythmic animals have deficits in spatial working memo

20 By contrast, arrhythmic animals made only random arm choices at all t

21 ing rescued spatial memory deficits in these arrhythmic animals.

22 cle in the livers of (1) wild-type mice, (2) arrhythmic Arntl knockout mice, (3) mice fed at regular

23 Period1/2/3 triple mutant mice, resulting in arrhythmic behavior in constant conditions.

24 splayed profound autonomic dysregulation and arrhythmic behavior in vivo.

25 ions and Ca(2+) sparks may contribute to the arrhythmic burden in heart failure.

26 d with neurohormonal activation, ventricular arrhythmic burden, and systolic/diastolic dysfunction (a

27 with a neurohormonal activation, ventricular arrhythmic burden, and worse prognosis.

28 SK blockade partially suppressed the arrhythmic burst pacing pattern of intact NCX KO SAN tis

29 Male and female adult hamsters were rendered arrhythmic by a disruptive phase shift protocol that eli

30 anslational studies because they can be made arrhythmic by a one-time photic treatment that severely

31 te sensitivity to alcohol, leading to sudden arrhythmic cardiac death in the second decade of life.

32 on fraction (LVEF), in prediction of adverse arrhythmic cardiac events (AACEs) in chronic ischemic he

33 iovascular deaths, predominantly of presumed arrhythmic cause.

34 Arrhythmic causes were found in 14% while no cause was i

35 phenotypes of PhLHY in Arabidopsis caused an arrhythmic clock phenotype, which resembles those of LHY

36 Moreover, in the lungs of the arrhythmic Clock(Delta19) mice, the levels of NRF2 and t

37 entrainment advantage is lost in plants with arrhythmic clocks or deficient in jasmonate hormone; thu

38 uman heart should be possible, but potential arrhythmic complications need to be overcome.

39 The outcome event was an arrhythmic composite end point of sudden cardiac death o

40 lar mortality or cardiac transplantation; an arrhythmic composite of SCD or aborted SCD (appropriate

41 The arrhythmic composite was reached by 42 patients with fib

42 vomilenine can be transformed into the anti-arrhythmic compound ajmaline, or alternatively, can isom

43 with cardiomyopathy and high risk inherited arrhythmic conditions and secondary prevention in surviv

44 are influenced by CSQ2 and are disrupted in arrhythmic conditions.

45 but not Clock or cycle, and persists in many arrhythmic conditions.

46 is effective in potentially eliminating the arrhythmic consequences of this genetic disease.

47 iac-specific gene expression and resulted in arrhythmic contracting cardiomyocytes in vitro.

48 We compared the incidence of arrhythmic contractions caused by norepinephrine, epinep

49 STAA ventricular myocytes exhibited arrhythmic contractions in response to isoproterenol, an

50 vation was augmented by specific patterns of arrhythmic correspondence.

51 Considerable research has described the arrhythmic course of arrhythmogenic right ventricular dy

52 endent bioluminescence rhythms in previously arrhythmic Cry1/2-deficient SCN, with periods appropriat

53 ciated with an increased risk of cardiac and arrhythmic death (P<0.001 for both).

54 Sudden arrhythmic death after myocardial infarction (MI) is mos

55 s of sudden death during endurance races are arrhythmic death and heat stroke.

56 nformation on resuscitated cardiac arrest or arrhythmic death at multiple time points (P<0.001).

57 Resuscitated cardiac arrest and arrhythmic death caused by ventricular tachyarrhythmias

58 sus testing by use of a composite outcome of arrhythmic death or failed appropriate shock (ie, a shoc

59 The primary outcome of arrhythmic death or failed appropriate shock occurred in

60 The primary endpoint was SCA defined as arrhythmic death or ICD discharge for ventricular fibril

61 ow-up, there were 33 sudden cardiac arrests (arrhythmic death or implantable cardiac defibrillator di

62 There was one arrhythmic death related to asystole in a single ventric

63 st common SCA-related conditions were sudden arrhythmic death syndrome (31%), coronary artery disease

64 IEW: Unexplained sudden death and the sudden arrhythmic death syndrome (SADS) affect a small but sign

65 Sudden arrhythmic death syndrome (SADS) describes a sudden deat

66 en identified in families affected by sudden arrhythmic death syndrome (SADS) remains unclear.

67 Sudden arrhythmic death syndrome (SADS) was the most prevalent

68 or the absence of cardiac pathology (sudden arrhythmic death syndrome [SADS]) at postmortem, directs

69 ric patients with a family history of sudden arrhythmic death syndrome assessed from 2010 to 2013 in

70 Sudden arrhythmic death syndrome defines a sudden unexpected an

71 Death caused by sudden arrhythmic death syndrome is more common at rest or duri

72 evaluation in pediatric relatives of sudden arrhythmic death syndrome probands.

73 ardiac death with a normal heart (ie, sudden arrhythmic death syndrome).

74 factors that distinguish patients at risk of arrhythmic death versus heart failure could better targe

75 The frequency of arrhythmic death was higher in patients with VT/VF than

76 Arrhythmic death was the primary cause of death in 13% o

77 However, "arrhythmic death" has caught practically all the attenti

78 associated with an increased risk of sudden arrhythmic death, and experimental evidence supports a t

79 therapies by the device and none suffered an arrhythmic death.

80 ut does not improve shock efficacy or reduce arrhythmic death.

81 sk factor for lethal cardiac arrhythmias and arrhythmic death.

82 diac death, resuscitated cardiac arrest, and arrhythmic death.

83 all-cause mortality, cardiac mortality, and arrhythmic death.

84 ox balance in the heart could prevent sudden arrhythmic death.

85 antable cardioverter-defibrillator efficacy (arrhythmic deaths and ineffective shocks), and composite

86 No arrhythmic deaths occurred during the follow-up.

87 and in patients not on digoxin, there were 2 arrhythmic deaths on dronedarone and 4 on placebo (P val

88 In patients on digoxin, there were 11 arrhythmic deaths on dronedarone and none on placebo; an

89 blockers could prevent hypoglycemia-induced arrhythmic deaths.

90 ic; it is unclear what proportion represents arrhythmic deaths.

91 r-240/786 microRNA cluster, which results in arrhythmic defecation, causes ectopic intestinal calcium

92 Voltage mapping revealed disorganized and arrhythmic depolarizations within the NCX KO SAN that fa

93 tissues produce a disproportionate burden of arrhythmic disease and are major predictors of mortality

94 ytes and provide a new platform for studying arrhythmic disorders leading to sudden cardiac death.

95 been as great as in cardiac channelopathies, arrhythmic disorders of genetic origin related to the io

96 Our study of behaviorally arrhythmic Drosophila circadian period mutants identifie

97 ors for simulation-guided approaches to anti-arrhythmic drug development and patient-specific therape

98 Anti-arrhythmic drug therapy is a frontline treatment for atr

99 be a predictor of the effectiveness of anti-arrhythmic drug therapy.

100 and patients without use of class I/III anti-arrhythmic drugs or digoxin.

101 Design of I(KS)-targeting anti-arrhythmic drugs requires detailed three-dimensional str

102 armacological agents (such as Class III anti-arrhythmic drugs).

103 ulation by the acute action of selected anti-arrhythmic drugs.

104 ily oscillations that are believed to become arrhythmic during aging.

105 ty of the model to reproduce potentially pro-arrhythmic dynamics under perturbed conditions, pertaini

106 BMAL1 C terminus including the TAD exhibited arrhythmic eclosion behavior.

107 of IKr and IKur produced a synergistic anti-arrhythmic effect in both forms of SQT3.

108 contradictory results on both pro- and anti-arrhythmic effects of blocking IKur.

109 reduces sympathetic activity and exerts anti-arrhythmic effects.

110 ricular dysfunction, cardiac remodeling, and arrhythmic episodes and improves survival.

111 GP-15, improves cardiac function and reduces arrhythmic episodes in two independent mouse models, whi

112 s the cumulative incidence of death or first arrhythmic event (defined as resuscitated cardiac arrest

113 No arrhythmic event occurred during class 1A AAD therapy in

114 04) were independent predictors of the first arrhythmic event on multivariable analysis.

115 he probability of experiencing a first major arrhythmic event or SCD during a lifetime was determined

116 The arrhythmic event rate during follow-up was low.

117 ession, genotype-phenotype correlations, and arrhythmic event rates in relatives carrying the Ryr2 mu

118 studies to document regional denervation for arrhythmic event risk assessment.

119 ary syndromes, myocardial revascularization, arrhythmic event, or stroke.

120 During a median follow-up of 34 months, 14 arrhythmic events (4.5%) occurred (13 appropriate shocks

121 was to determine whether mexiletine prevents arrhythmic events (arrhythmic syncope, aborted cardiac a

122 and QRS duration were greater in those with arrhythmic events (both P<0.001) and this was consistent

123 +/- 0.03; p = 0.027), and the annual rate of arrhythmic events (from 10.3% to 0.7%; p = 0.0097).

124 and reduced the percentage of patients with arrhythmic events (from 22% to 3%; p = 0.031), the mean

125 p, only QRSp was an independent predictor of arrhythmic events (hazard ratio, 2.1; P<0.001).

126 Q reduces the occurrence of life-threatening arrhythmic events (LAE) (cardiac arrest or sudden cardia

127 e of ARVC and occurrence of life-threatening arrhythmic events (LAE) and cardiovascular mortality; id

128 of 2.3 (95% CI: 0.63-8.66; p=0.2) for major arrhythmic events (sustained VAs, sudden cardiac death,

129 ppear to be associated with a higher risk of arrhythmic events after operation.

130 ascular events, and accounted for a third of arrhythmic events after the procedure.

131 determine the impact on therapy changes and arrhythmic events after the procedure.

132 y identify asymptomatic patients at risk for arrhythmic events and could be helpful in investigating

133 gical cryoablation does not seem to increase arrhythmic events and may be protective.

134 patients evaluating the association between arrhythmic events and predictive tests (baroreflex sensi

135 as a powerful risk factor for lifetime major arrhythmic events and SCD.

136 tonomic innervation of the heart may trigger arrhythmic events and stellectomy is a treatment option

137 of genotype for prediction of lifetime major arrhythmic events and sudden cardiac death (SCD) in desm

138 Nevertheless, arrhythmic events and sudden cardiac death are not negli

139 d with the PMCA1(loxP/loxP) hearts, and such arrhythmic events became more severe under Ca(2+) overlo

140 All arrhythmic events but one were asymptomatic and led to a

141 greater mortality and a higher incidence of arrhythmic events compared to norepinephrine administrat

142 ic events per patient and the annual rate of arrhythmic events during observation periods of equal du

143 Arrhythmic events in asymptomatic Brugada syndrome patie

144 (QRSp) in high-resolution ECGs would predict arrhythmic events in implantable cardioverter-defibrilla

145 caused a major reduction of life-threatening arrhythmic events in LQT3 patients, thus representing an

146 des novel insights into risk of breakthrough arrhythmic events in LQTS, particularly LQT2.

147 d risk stratification tests as predictors of arrhythmic events in patients with nonischemic dilated c

148 ection fraction for the prediction of future arrhythmic events in patients with systolic dysfunction

149 ghts the importance of an early diagnosis of arrhythmic events in such patients to implement the appr

150 time of 74.3+/-57.3 months (median 57.3), 25 arrhythmic events occurred (16 in the inducible group an

151 Arrhythmic events occurred in only 2 cardiac arrest surv

152 mean follow-up time of 73.2+/-58.9 months, 9 arrhythmic events occurred, accounting for an annual inc

153 om 22% to 3%; p = 0.031), the mean number of arrhythmic events per patient (from 0.43 +/- 0.17 to 0.0

154 acy of mexiletine by comparing the number of arrhythmic events per patient and the annual rate of arr

155 sted information concerning cases of adverse arrhythmic events resulting from unavailability of quini

156 tes with stria pattern experienced malignant arrhythmic events such as appropriate implantable cardia

157 bilize the action potential and suppress pro-arrhythmic events than the rapid delayed rectifier.

158 a(2+) uptake by PLN ablation can prevent the arrhythmic events triggered by SR Ca(2+) leak due to CaM

159 The primary end point of arrhythmic events was defined as appropriate ICD therapy

160 r Kaplan-Meier estimates of the incidence of arrhythmic events were 7% among patients who underwent a

161 r Kaplan-Meier estimates of the incidence of arrhythmic events were 7% among patients who underwent a

162 xperienced >/=1 defined breakthrough cardiac arrhythmic events with 5- and 10-year event rates of 4%

163 sex were independent predictors of lifetime arrhythmic events with a hazard ratio of 3.71 (95% confi

164 ysis revealed that a QRSp >/=2.25 identified arrhythmic events with greater sensitivity (100% versus

165 (Prediction of ARrhythmic Events With Positron Emission Tomography [PAR

166 The PAREPET (Prediction of ARrhythmic Events with Positron Emission Tomography) stu

167 ealth-sponsored PAREPET trial (Prediction of Arrhythmic Events with Positron Emission Tomography).

168 oronary syndromes, 28 revascularizations, 22 arrhythmic events, and 2 strokes).

169 with increased age-dependent risk for major arrhythmic events, and paradoxical responses to beta-adr

170 e of cardiovascular death, heart failure, or arrhythmic events, for patients with or without TTNtv (h

171 HRT is a powerful predictor of both CD and arrhythmic events, particularly in postacute myocardial

172 5% CI, 2.2-3.3) for total mortality, CD, and arrhythmic events, respectively.

173 atients (16%) from 20 different families had arrhythmic events, such as SCD (n=1), aborted SCD becaus

174 -56) months, 19 (27.5%) patients experienced arrhythmic events, such as sudden death (n=1), appropria

175 eased isometric twitch of the myocardium and arrhythmic events, suggesting that Galphaq-protein-coupl

176 isting clinical metrics in predicting future arrhythmic events.

177 ated with worsening heart failure as well as arrhythmic events.

178 ing to false detection of atrial/ventricular arrhythmic events.

179 pe I electrocardiogram have a higher risk of arrhythmic events.

180 )/Ca(2+) exchange, an important mechanism of arrhythmic events.

181 nction is a strong, independent predictor of arrhythmic events.

182 nts represented a significant portion of all arrhythmic events.

183 s) increased the predictive power for CD and arrhythmic events.

184 of 24 (15-43) months, 20 (20%) patients had arrhythmic events.

185 ith cause-specific mortality (heart failure, arrhythmic) examined in secondary analyses.

186 methods to identify and locate the origin of arrhythmic excitation.

187 g sic-1 mutant both exhibit low-amplitude or arrhythmic expression of core circadian clock genes unde

188 nt successful radiofrequency ablation of the arrhythmic focus without ventricular tachycardia recurre

189 gene expression are abolished in a circadian arrhythmic frq(ko) mutant.

190 tor itself, whose mutation causes completely arrhythmic gene expression.

191 ed novel objects from familiar ones, whereas arrhythmic hamsters could not.

192 lenetetrazole (PTZ; 0.3 or 1.0 mg/kg/day) to arrhythmic hamsters for 10 days, which is a regimen prev

193 erential gene expression in entrained versus arrhythmic hamsters in the suprachiasmatic nucleus (SCN)

194 ory persisted for at least 3 weeks after the arrhythmic hamsters were switched back to ad libitum fee

195 properties are consistent characteristics in arrhythmic heart disease.

196 Pro-arrhythmic implications of measured LV/RV functional dif

197 ce of core circadian clock genes also became arrhythmic in the rNAD-ME1 line, suggesting that perturb

198 : 32 cm/s, PP1: 41 cm/s, p < 0.05) and lower arrhythmic inducibility (PP3: 71%, PP1: 35%, p < 0.05) t

199 that link loss of sodium channel function to arrhythmic instability remain unresolved.

200 mic nervous system is pro-arrhythmic or anti-arrhythmic is multifaceted and varies for different type

201 rmalities, repolarization abnormalities, and arrhythmic markers provide only modest risk stratificati

202 sly calcifying tendons in young CLOCKDelta19 arrhythmic mice and aged wild-type mice.

203 Arrhythmic mitral valve prolapse (MVP) is characterized

204 ernating hemiplegia of childhood, as cardiac arrhythmic morbidity and mortality are potentially preve

205 ICD therapy reduced arrhythmic mortality in the top 2 tertiles of 6MW, but h

206 tic link between this ECG pattern and higher arrhythmic mortality of middle-aged/elderly subjects.

207 o heart failure-related mortality but not to arrhythmic mortality.

208 x (27 female patients; median age: 44 years) arrhythmic MVP patients with LV late gadolinium enhancem

209 annulus disjunction is a constant feature of arrhythmic MVP with LV fibrosis.

210 by which the autonomic nervous system is pro-arrhythmic or anti-arrhythmic is multifaceted and varies

211 ythms: pdf(01) (pdf-null) animals are mostly arrhythmic or short period in constant darkness and have

212 ng-state power fluctuations of broadband and arrhythmic, or scale-free, macaque electrocorticography

213 Clinical, electrocardiographic, and arrhythmic outcome (composite measure of first occurrenc

214 low-voltage area was a powerful predictor of arrhythmic outcome in ARVC/D, independently of history a

215 Univariate predictors of arrhythmic outcome included previous cardiac arrest or s

216 The clinical profile and arrhythmic outcome of competitive athletes with isolated

217 f 7 years, 86 (40%) patients experienced the arrhythmic outcome.

218 sensitivity) were significant predictors of arrhythmic outcomes.

219 plore the use of simulations to improve anti-arrhythmic pacing and defibrillation interventions; to p

220 11beta-HSD2 was up-regulated by arrhythmic pacing in cultured cardiomyocytes and in a mo

221 t hyperactivation of SK channels, leading to arrhythmic pauses alternating with bursts of pacing.

222 get of PDF, we rescued per in PDF neurons of arrhythmic per(0)(1) mutants.

223 13.5, the anlagen of the SCN expresses high, arrhythmic PER2.

224 ation led to bradycardia in zebrafish and an arrhythmic phenotype in a subset of the analyzed zebrafi

225 The arrhythmic phenotype of cardiac-Sirt1-deficient mice rec

226 reas its inhibitor KN93 or AIP abolished the arrhythmic phenotype.

227 -) RV epicardium, directly predictive of its arrhythmic phenotype.

228 In hypertrophic cardiomyopathy (HCM), the arrhythmic potential associated with a variety of left v

229 A deeper understanding of the underlying arrhythmic principles is mandatory if we are to improve

230 ian rhythmicity modulator), which results in arrhythmic promoter activity but does not affect steady-

231 d ingestion, whereas activating them elicits arrhythmic pumping.

232 important factor in determining whether pro-arrhythmic release patterns develop.

233 important factor in determining whether pro-arrhythmic release patterns develop.

234 onal factor contributing to the differential arrhythmic risk among patients with LQT1 carrying the sa

235 ver, data regarding the effect of statins on arrhythmic risk among patients with NICM are limited.

236 ulating variant levels were correlative with arrhythmic risk as measured by ICD events in an HF popul

237 alysis program in defining breakthrough LQTS arrhythmic risk beyond the QTc value.

238 Mild hypertrophy but increased arrhythmic risk characterizes the stereotypic phenotype

239 ompared with thick-filament disease, whereas arrhythmic risk in both subsets is comparable.

240 that targeted regulation of Cav1 may reduce arrhythmic risk in cardiac diseases associated with reni

241 These processes may explain the increased arrhythmic risk in kidney disease and aid in identifying

242 tant parameters to consider when determining arrhythmic risk include electric instability, including

243 ics of DCM and how specific mutations affect arrhythmic risk is also rapidly increasing.

244 Determination of ventricular arrhythmic risk is crucial for guiding management of car

245 ing, and cardiac magnetic resonance enhances arrhythmic risk stratification beyond ejection fraction

246 ve genetic screening of desmosomal genes for arrhythmic risk stratification in ARVC.

247 Holter examination provide for comprehensive arrhythmic risk stratification in patients with arrhythm

248 cardiac magnetic resonance (CMR) imaging in arrhythmic risk stratification of arrhythmogenic right v

249 ck, may identify MVP patients who would need arrhythmic risk stratification.

250 Incremental arrhythmic risk was seen in patients with increasing pre

251 s as an unintended side effect also increase arrhythmic risk.

252 end-stage progression, and stratification of arrhythmic risk.

253 varying degrees of phenotypic expression and arrhythmic risk.

254 d with CRT-D therapy was suggested to reduce arrhythmic risk.

255 binding kinetics might display divergent pro-arrhythmic risks.

256 ensitive nature of SK channels could explain arrhythmic SAN pacemaker activity in the atrial-specific

257 ratification to identify patients at risk of arrhythmic SCD is essential for targeting our healthcare

258 MVP is an underestimated cause of arrhythmic SCD, mostly in young adult women.

259 a GABAergic nucleus, we hypothesized that an arrhythmic SCN could interfere with memory by increasing

260 )] restores autonomous circadian activity in arrhythmic SCN-lesioned (SCNX) C3H/HeN mice.

261 Circadian-arrhythmic Siberian hamsters (Phodopus sungorus) exhibit

262 iteria, allows for a direct visualization of arrhythmic spiral re-entry and represents a revolutionar

263 mplitude, SR Ca(2+) load, and latency of pro-arrhythmic spontaneous Ca(2+) waves (SCWs) were decrease

264 effects on the heart that associate with pro-arrhythmic spontaneous Ca(2+) waves.

265 itum feeding, locomotor activity resumed its arrhythmic state, but performance on the SA task varied

266 Patients with refractory arrhythmic storm admitted between January 2005 and March

267 Patients with intractable refractory arrhythmic storm and cardiogenic shock despite optimal m

268 achycardias (VTs; cycle lengths, 230-740 ms, arrhythmic storm n=28) and 2 ventricular fibrillation tr

269 racorporeal life support to treat refractory arrhythmic storm responsible for cardiogenic shock in pa

270 h extracorporeal life support for refractory arrhythmic storm responsible for cardiogenic shock resis

271 in the last hour of their lives; 24% had an arrhythmic storm, and 31% received shock treatment durin

272 Our results suggest that anti-arrhythmic strategies that increase atrial APD without i

273 ns and promotes the progress of current anti-arrhythmic strategies.

274 artial inhibition of IKs as a potential anti-arrhythmic strategy in SQT2.

275 ko) hearts became more susceptible to atrial arrhythmic stress conditions than PMCA1(loxP/loxP) heart

276 We found that once animals are made arrhythmic, subsequent SCN ablation completely rescues m

277 approach that could improve the efficacy of arrhythmic substrate ablation in the thick ventricular m

278 f cardiac magnetic resonance for imaging the arrhythmic substrate, both as a research tool and for cl

279 guided by direct pathophysiologic markers of arrhythmic substrate, such as specific left ventricular

280 lation with acetic acid enabled the intended arrhythmic substrate, whether deep or superficial, to be

281 tion similar to humans, to better define the arrhythmic substrate.

282 Arrhythmic sudden cardiac death (SCD) may be caused by v

283 hod for visualizing the myocardial origin of arrhythmic sudden cardiac death.

284 death occurred in 18 patients (3%; 0.54%/y): arrhythmic sudden death (n=12), progressive heart failur

285 ng events: progressive heart failure (n=17); arrhythmic sudden death (SD) (n=17); and embolic stroke

286 ith LV apical aneurysms are at high risk for arrhythmic sudden death and thromboembolic events.

287 n=3), postoperative complications (n=2), and arrhythmic sudden death events (n=5, 1.2% [0.20%/y]).

288 or more of its major disease pathways (i.e., arrhythmic sudden death risk; progressive heart failure

289 tor to heart failure morbidity or a cause of arrhythmic sudden death; when treated, it is associated

290 er 100 patient-years; HR, 0.87; P = .50) and arrhythmic syncope rates (3.1 [95% CI, 2.6-4.6] vs 1.9 [

291 fibrillation [AF], and 4% with a history of arrhythmic syncope).

292 ether mexiletine prevents arrhythmic events (arrhythmic syncope, aborted cardiac arrest, or sudden ca

293 r changing atrial conduction and age-related arrhythmic tendency.

294 h Cry1(-/-);Cry2(-/-) mice were behaviorally arrhythmic, their SCN expressed short period (~18 h) rhy

295 The arrhythmic transcription of core circadian genes and dow

296 Arrhythmic translation caused by temporal stalling of ri

297 y provide important insights into novel anti-arrhythmic treatments in heart failure.

298 S, absence of acute coronary syndrome as the arrhythmic trigger, and >/=10 patients included.

299 -ran in rats under a RGB:RG cycle and became arrhythmic under RGB:RGV.

300 rdiac pressure and occurrence of ventricular arrhythmic (VT/VF) events.